{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+\/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence","item":"https:\/\/www.regionalcancercare.org\/trials\/cambria-1-a-phase-iii-open-label-randomised-study-to-assess-the-efficacy-and-safety-of-extended-therapy-with-camizestrant-azd9833-a-next-generation-oral-selective-estrogen-receptor-degrader-ver\/#breadcrumbitem"}]}